Medical School · Year 3 · Family Medicine · includes a quiz and discussion video

Seminar 06: Hypertension and Cardiovascular Risk

Year 3: Family Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Diagnose hypertension using appropriate measurement techniques
2. Classify blood pressure and assess cardiovascular risk
3. Apply lifestyle modifications for hypertension
4. Select appropriate antihypertensive medications
5. Manage resistant and secondary hypertension
6. Integrate cardiovascular risk reduction strategies

Seminar Outline

I. Blood Pressure Measurement

Accurate blood pressure measurement requires meticulous attention to technique, as errors at this fundamental step lead to misdiagnosis and inappropriate treatment. Patients should rest quietly for at least five minutes before measurement in a seated position with back supported, feet flat on the floor, and the arm supported at heart level. The bladder should be emptied before measurement, and neither patient nor clinician should talk during the procedure. Cuff size must match arm circumference, with the bladder encircling at least eighty percent of the arm; undersized cuffs falsely elevate readings while oversized cuffs underestimate pressure. Multiple readings should be obtained and averaged, as single measurements provide unreliable estimates of usual blood pressure.

Out-of-office blood pressure monitoring provides essential information for accurate diagnosis and ongoing management. Home blood pressure monitoring involves patients measuring their pressure using validated automated devices, ideally taking readings in the morning and evening for seven days with averages calculated excluding the first day. Ambulatory blood pressure monitoring represents the gold standard, capturing readings every fifteen to thirty minutes over twenty-four hours to characterize blood pressure throughout daily activities and sleep. Out-of-office monitoring identifies white coat and masked hypertension patterns that would otherwise lead to misclassification and detects nocturnal blood pressure abnormalities associated with increased cardiovascular risk.

White coat hypertension and masked hypertension represent opposing patterns of discrepancy between office and out-of-office blood pressure that carry different prognostic implications. White coat hypertension, affecting fifteen to thirty percent of patients with elevated office readings, describes elevated office pressure with normal home or ambulatory measurements, reflecting an alerting response to the clinical environment. Masked hypertension, present in ten to fifteen percent of those with normal office readings, describes normal office pressure with elevated out-of-office measurements. This distinction matters clinically because masked hypertension carries cardiovascular risk equivalent to sustained hypertension and requires treatment despite reassuring office readings.

Accurate hypertension diagnosis requires confirmation through appropriate testing sequence. Initial elevated readings should prompt repeat measurement at the same visit after additional rest. Stage 1 hypertension at borderline elevations warrants confirmation through home or ambulatory monitoring before initiating treatment. Stage 2 hypertension with substantially elevated readings may be confirmed on the basis of two office visits given the lower likelihood of measurement artifact at higher values. Documentation should record measurement technique, cuff size, and number of readings averaged to enable appropriate interpretation of results.

<image>Panel A: Proper blood pressure measurement technique illustrated step-by-step with common errors noted. Panel B: Home blood pressure monitoring protocol showing timing, frequency, and recording method. Panel C: Two-by-two grid comparing white coat versus masked versus sustained hypertension with office and home readings. Panel D: Diagnostic confirmation flowchart showing pathway from initial elevated reading to confirmed diagnosis.</image>

II. Classification and Staging

Current blood pressure classification under the 2017 American College of Cardiology and American Heart Association guidelines defines four categories with progressively higher cardiovascular risk. Normal blood pressure requires systolic below 120 mmHg and diastolic below 80 mmHg. Elevated blood pressure encompasses systolic 120 to 129 mmHg with diastolic below 80 mmHg. Stage 1 hypertension includes systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg. Stage 2 hypertension covers systolic at or above 140 mmHg or diastolic at or above 90 mmHg. Hypertensive crisis requires urgent evaluation when systolic exceeds 180 mmHg or diastolic exceeds 120 mmHg.

Blood pressure targets should aim for less than 130/80 mmHg in most patients based on evidence demonstrating cardiovascular event reduction at this threshold compared to higher targets. This target applies broadly to patients with high cardiovascular risk, diabetes, chronic kidney disease, and secondary stroke prevention. Elderly patients aged 65 and older should also target systolic below 130 mmHg when tolerated, though treatment decisions require careful attention to fall risk, orthostatic symptoms, and medication burden. More relaxed targets may be appropriate for patients with limited life expectancy, significant frailty, or adverse effects from intensive treatment.

Cardiovascular risk assessment using the atherosclerotic cardiovascular disease (ASCVD) risk calculator contextualizes blood pressure within overall cardiovascular risk profile. This tool estimates ten-year risk of heart attack and stroke based on age, sex, race, total and HDL cholesterol, blood pressure, diabetes status, and smoking history. Risk categories span low (below five percent), borderline (five to 7.5 percent), intermediate (7.5 to twenty percent), and high (above twenty percent). Risk assessment informs treatment intensity, as higher cardiovascular risk lowers the blood pressure threshold at which pharmacotherapy becomes beneficial.

Treatment thresholds integrate blood pressure stage with cardiovascular risk to guide medication decisions. All patients with blood pressure at or above 140/90 mmHg should receive antihypertensive medication regardless of cardiovascular risk level. Patients with stage 1 hypertension (130-139/80-89 mmHg) should receive medication if their ten-year ASCVD risk exceeds ten percent or if they have established atherosclerotic cardiovascular disease, diabetes, or chronic kidney disease. Lower-risk patients with stage 1 hypertension should attempt lifestyle modification first, with medication added if blood pressure remains uncontrolled after three to six months.

<image>Panel A: Blood pressure classification grid showing categories with systolic and diastolic thresholds. Panel B: Target blood pressure by population with supporting evidence summary. Panel C: ASCVD risk calculator inputs and risk category definitions with example calculations. Panel D: Treatment threshold decision matrix integrating blood pressure stage and cardiovascular risk.</image>

III. Initial Evaluation

History taking for newly diagnosed hypertension gathers information relevant to risk stratification, secondary cause identification, and treatment planning. Duration of hypertension and prior treatment responses guide medication selection. Symptoms including headache, visual changes, chest pain, or dyspnea may suggest target organ damage or hypertensive urgency. Lifestyle factors encompassing dietary sodium, alcohol consumption, physical activity level, and sleep patterns identify modifiable contributors. Family history of hypertension and premature cardiovascular disease informs risk assessment. Medication review captures prescription and over-the-counter drugs that may elevate blood pressure including NSAIDs, decongestants, and stimulants.

Physical examination focuses on identifying target organ damage and clues to secondary hypertension. Fundoscopic examination may reveal hypertensive retinopathy including arteriovenous nicking, hemorrhages, or papilledema in severe cases. Thyroid palpation screens for thyroid disease causing secondary hypertension. Cardiovascular examination detects S4 gallops suggesting left ventricular stiffness, murmurs indicating valvular disease, and irregular rhythms warranting arrhythmia evaluation. Abdominal examination listens for renal artery bruits suggesting renovascular hypertension. Peripheral pulse assessment identifies pulse deficits suggesting coarctation or peripheral arterial disease, while lower extremity edema may indicate heart failure or chronic kidney disease.

Initial laboratory testing establishes baseline values and screens for target organ damage and secondary causes. Complete metabolic panel provides creatinine and estimated GFR for renal function assessment plus electrolytes that may reveal primary aldosteronism or renal disease. Fasting lipid panel contributes to cardiovascular risk calculation. Fasting glucose or hemoglobin A1c screens for diabetes, which affects risk assessment and medication selection. Urinalysis detects proteinuria indicating renal involvement. Electrocardiogram screens for left ventricular hypertrophy, prior myocardial infarction, and arrhythmias. Additional testing including thyroid function and uric acid may be appropriate based on clinical suspicion.

Target organ damage identification influences treatment urgency and intensity. Cardiac manifestations include left ventricular hypertrophy on electrocardiogram or echocardiogram, coronary artery disease, and heart failure. Cerebrovascular disease encompasses stroke, transient ischemic attack, and vascular cognitive impairment. Renal involvement manifests as chronic kidney disease with reduced GFR or albuminuria. Hypertensive retinopathy grades from mild arteriovenous nicking through hemorrhages to papilledema indicating malignant hypertension. Peripheral arterial disease indicates systemic atherosclerosis with increased cardiovascular risk. Presence of target organ damage generally warrants more aggressive blood pressure targets and often specific medication classes.

<image>Panel A: Hypertension history checklist organized by symptoms, lifestyle, family, and medications. Panel B: Physical examination findings relevant to hypertension with locations and significance. Panel C: Initial laboratory panel with tests, purposes, and interpretation guides. Panel D: Target organ damage manifestations by organ system with clinical implications.</image>

IV. Lifestyle Modifications

The Dietary Approaches to Stop Hypertension (DASH) diet represents the most evidence-based dietary pattern for blood pressure reduction. This eating plan emphasizes four to five daily servings each of fruits and vegetables, six to eight servings of whole grains, and two to three servings of low-fat dairy products. Protein sources focus on lean meats, poultry, fish, and nuts while minimizing red meat and sweets. The combination of increased potassium, calcium, magnesium, and fiber with reduced saturated fat produces blood pressure reductions averaging eleven mmHg systolic, rivaling the effect of single antihypertensive medications. Successful implementation requires patient education on serving sizes and practical strategies for food selection and preparation.

Sodium reduction provides additional blood pressure benefit independent of overall dietary pattern. Ideal sodium intake targets below 1500 mg daily, though any reduction from typical American intake averaging over 3400 mg daily proves beneficial. Reduction of 1000 mg daily produces average blood pressure decrease of five to six mmHg. Practical counseling emphasizes reading nutrition labels, limiting processed and restaurant foods which contribute most dietary sodium, and using herbs and spices rather than salt for flavoring. Patients often underestimate their sodium intake because most comes from packaged and prepared foods rather than added table salt.

Additional lifestyle modifications contribute cumulative blood pressure benefits when combined. Weight loss produces approximately one mmHg systolic reduction per kilogram lost, making this intervention particularly powerful for overweight patients. Regular aerobic physical activity including brisk walking, jogging, cycling, or swimming for 150 minutes weekly reduces systolic pressure by five to eight mmHg. Limiting alcohol to no more than two drinks daily for men or one for women yields four mmHg reduction in those who drink excessively. Smoking cessation does not directly lower blood pressure but dramatically reduces cardiovascular risk. Stress management through meditation, relaxation techniques, or cognitive behavioral approaches may provide modest additional benefit.

Implementing lifestyle changes successfully requires realistic patient-centered approaches. Prioritization should focus on changes most likely to benefit the individual patient based on their current habits and risk profile. Starting with small achievable steps builds confidence and establishes habits before advancing to more ambitious goals. Professional support from dietitians, exercise physiologists, or health coaches enhances success rates for patients who can access these resources. Regular monitoring of blood pressure provides feedback that reinforces the connection between lifestyle changes and tangible results. Progress review at each visit maintains focus and allows troubleshooting of challenges.

<image>Panel A: DASH diet pyramid showing food groups, serving sizes, and blood pressure effects. Panel B: Sodium reduction strategies with typical foods and lower-sodium alternatives. Panel C: Lifestyle modification summary showing blood pressure effects of each intervention. Panel D: Lifestyle change implementation framework with assessment, prioritization, and follow-up elements.</image>

V. Pharmacotherapy Overview

Four medication classes constitute appropriate first-line therapy for most patients with hypertension. Thiazide and thiazide-like diuretics including hydrochlorothiazide, chlorthalidone, and indapamide reduce blood volume and peripheral resistance. Angiotensin-converting enzyme (ACE) inhibitors such as lisinopril and enalapril block the renin-angiotensin system. Angiotensin receptor blockers (ARBs) including losartan and valsartan also target this pathway through a different mechanism. Calcium channel blockers such as amlodipine and diltiazem reduce vascular smooth muscle contraction. All four classes demonstrate comparable blood pressure lowering efficacy and cardiovascular event reduction in clinical trials.

Medication selection should be guided by compelling indications based on comorbidities that favor specific drug classes. Patients with diabetes and proteinuria benefit from ACE inhibitors or ARBs given their renal protective effects. Heart failure patients should receive ACE inhibitors or ARBs along with beta-blockers and diuretics as foundational therapy. Chronic kidney disease similarly favors ACE inhibitors or ARBs for their antiproteinuric effects. Post-myocardial infarction management includes ACE inhibitors and beta-blockers. Patients with stable coronary artery disease benefit from beta-blockers and ACE inhibitors. Black patients demonstrate better blood pressure response to thiazide diuretics and calcium channel blockers as initial monotherapy. Pregnancy requires avoidance of ACE inhibitors and ARBs in favor of labetalol, nifedipine, or methyldopa.

Initial treatment intensity depends on blood pressure severity and baseline cardiovascular risk. Stage 1 hypertension may be appropriately treated with a single antihypertensive agent at low to moderate doses. Stage 2 hypertension, defined as blood pressure at or above 140/90 mmHg or more than twenty points systolic or ten points diastolic above goal, often requires initial dual therapy for adequate control. Combination therapy using two drugs from complementary classes proves more effective than high-dose monotherapy and may reduce side effects through lower individual drug doses. Follow-up four to six weeks after initiating or adjusting therapy allows assessment of response and further titration.

Effective drug combinations pair medications with complementary mechanisms of action. ACE inhibitors or ARBs combined with calcium channel blockers represent a well-tolerated effective combination. ACE inhibitors or ARBs paired with thiazide diuretics offer another evidence-based option with the added benefit that renin-angiotensin blockade reduces diuretic-induced hypokalemia. Calcium channel blockers combined with thiazide diuretics provide effective blood pressure control without metabolic effects. Combining ACE inhibitors with ARBs should be avoided due to increased adverse events without additional benefit. Similarly, adding direct renin inhibitors to ACE inhibitors or ARBs is not recommended.

<image>Panel A: First-line medication class overview with agents, mechanisms, and typical dosing. Panel B: Compelling indications matrix matching comorbidities to preferred medication classes. Panel C: Treatment intensity selection based on blood pressure level and starting approach. Panel D: Preferred combination therapy pairings with complementary mechanisms.</image>

VI. Specific Medication Classes

Thiazide diuretics inhibit sodium reabsorption in the distal convoluted tubule, producing natriuresis that reduces blood volume and subsequently peripheral vascular resistance. Chlorthalidone, with its longer half-life and greater potency, may provide superior blood pressure control and cardiovascular outcomes compared to hydrochlorothiazide, though both remain widely used. Low doses of 12.5 to 25 mg daily often achieve maximal antihypertensive effect with fewer metabolic side effects than higher doses. Important adverse effects include hypokalemia requiring monitoring and possible supplementation, hyperuricemia that may precipitate gout, hyperglycemia that may unmask latent diabetes, and hyponatremia particularly in elderly patients. Electrolyte monitoring at two to four weeks after initiation helps detect these metabolic effects early.

Angiotensin-converting enzyme inhibitors prevent conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion while increasing beneficial bradykinin levels. These agents provide particular benefit in diabetes with proteinuria, heart failure, and post-myocardial infarction through mechanisms extending beyond blood pressure reduction. Dry cough affects approximately ten percent of patients and results from bradykinin accumulation; this side effect is class-wide and necessitates switching to ARBs when intolerable. Angioedema, though rare, represents a potentially life-threatening reaction requiring permanent discontinuation of all ACE inhibitors. Hyperkalemia risk increases with renal impairment and concomitant potassium-sparing agents. Absolute contraindication applies to pregnancy due to fetal toxicity and bilateral renal artery stenosis due to acute kidney injury risk. Monitoring creatinine and potassium at one to two weeks after initiation detects early adverse effects.

Calcium channel blockers divide into dihydropyridine and non-dihydropyridine subclasses with different properties. Dihydropyridines including amlodipine produce primarily vascular smooth muscle relaxation and peripheral vasodilation; their main side effect is dose-dependent peripheral edema from precapillary dilation. Non-dihydropyridines including diltiazem and verapamil also reduce cardiac contractility and heart rate, making them useful for rate control in atrial fibrillation but contraindicated in heart failure with reduced ejection fraction. Benefits of calcium channel blockers include metabolic neutrality without effects on glucose or lipids and excellent efficacy across demographic groups. Constipation affects some patients, particularly with verapamil, while gingival hyperplasia occurs rarely.

Beta-adrenergic blockers reduce cardiac output and renin release but no longer represent first-line therapy for uncomplicated hypertension given inferior cardiovascular protection compared to other classes. However, beta-blockers remain essential for patients with compelling indications including heart failure with reduced ejection fraction, post-myocardial infarction, and atrial fibrillation requiring rate control. Common agents include metoprolol, carvedilol which adds alpha-blocking activity, and atenolol. Adverse effects include bradycardia, fatigue, exercise intolerance, and bronchospasm limiting use in asthma. Sexual dysfunction affects some male patients. Abrupt discontinuation risks rebound hypertension and should be avoided.

<image>Panel A: Thiazide diuretic profile with mechanism, preferred agents, dosing, and metabolic effects. Panel B: ACE inhibitor characteristics including benefits, cough management, and monitoring requirements. Panel C: Calcium channel blocker comparison between dihydropyridine and non-dihydropyridine subclasses. Panel D: Beta-blocker indications, limitations as first-line therapy, and side effect profile.</image>

VII. Resistant Hypertension

Resistant hypertension is defined as blood pressure remaining above goal despite treatment with optimal doses of three antihypertensive medications from different classes including a diuretic. True resistant hypertension affects ten to fifteen percent of treated hypertensive patients and carries substantially elevated cardiovascular risk. However, apparent resistance often results from addressable factors that must be excluded before diagnosing true resistance, making systematic evaluation essential before escalating therapy.

Causes of apparent resistance encompass measurement issues, adherence problems, and interfering factors. White coat effect may cause persistently elevated office readings despite adequate out-of-office control; ambulatory or home blood pressure monitoring distinguishes this pattern. Non-adherence to prescribed medications represents the most common cause of apparent treatment failure; assessment through non-judgmental discussion, pharmacy refill records, and pill counts helps identify this barrier. Suboptimal dosing with medications below maximally effective levels limits blood pressure reduction. Drug interactions including NSAIDs causing sodium retention and vasoconstriction, sympathomimetics in decongestants, and certain antidepressants may counteract antihypertensive effects.

Secondary causes of hypertension warrant consideration in patients with resistant hypertension, early-onset hypertension before age 30, sudden worsening of previously controlled blood pressure, or clinical features suggesting specific etiologies. Primary aldosteronism, now recognized in five to ten percent of hypertensive patients, presents with hypokalemia (though not always present) and may be screened by measuring the aldosterone-to-renin ratio. Renal artery stenosis from atherosclerosis in older patients or fibromuscular dysplasia in younger women may present with resistant hypertension, flash pulmonary edema, or greater than thirty percent creatinine rise after starting ACE inhibitors or ARBs. Pheochromocytoma causes paroxysmal hypertension with the classic triad of headache, sweating, and palpitations. Obstructive sleep apnea strongly associates with resistant hypertension, particularly in obese patients with snoring and daytime fatigue.

Management of true resistant hypertension requires maximizing existing therapy and adding appropriate agents. Ensuring optimal diuretic therapy is essential, with chlorthalidone preferred over hydrochlorothiazide given greater potency. Adding spironolactone at 25 to 50 mg daily proves highly effective in resistant hypertension, likely because undiagnosed hyperaldosteronism contributes to many cases; potassium monitoring is essential. Additional agents for refractory cases include clonidine, hydralazine, and minoxidil, though side effects limit their use. Reinforcing lifestyle modifications including strict sodium restriction and weight loss augments pharmacologic therapy. Referral to a hypertension specialist is appropriate when blood pressure remains uncontrolled despite these measures.

<image>Panel A: Resistant hypertension definition with diagnostic criteria and prevalence. Panel B: Apparent resistance causes organized by measurement, adherence, and interfering factors. Panel C: Secondary hypertension causes with clinical clues and initial screening tests. Panel D: Resistant hypertension treatment algorithm showing optimization, spironolactone addition, and escalation steps.</image>

VIII. Secondary Hypertension

Clinical features should raise suspicion for secondary hypertension warranting evaluation beyond routine testing. Age of onset before 30 years in the absence of obesity or family history suggests secondary causes in this atypical demographic. Resistance to three or more medications including a diuretic indicates potential underlying etiology driving blood pressure elevation. Sudden severe elevation or acute worsening of previously stable blood pressure may signal new secondary cause development. Target organ damage disproportionate to hypertension duration suggests more severe underlying disorder. Laboratory abnormalities including unprovoked hypokalemia or elevated creatinine provide clues to specific secondary causes.

Primary aldosteronism results from autonomous aldosterone secretion causing sodium retention, potassium wasting, and hypertension. Screening with the aldosterone-to-renin ratio detects most cases, with ratios exceeding 30 suggesting the diagnosis. Prevalence among hypertensive patients reaches five to ten percent, making this the most common secondary cause. Hypokalemia, though classically associated, is absent in many cases and should not be required to pursue evaluation. Confirmatory testing with salt loading differentiates true aldosteronism from other causes of elevated aldosterone. Treatment involves surgical resection for unilateral adenomas or mineralocorticoid receptor antagonists for bilateral hyperplasia.

Renal artery stenosis presents differently depending on underlying etiology. Atherosclerotic stenosis typically affects older patients with generalized vascular disease and may manifest as resistant hypertension, flash pulmonary edema, or acute kidney injury after starting renin-angiotensin system blockers. Fibromuscular dysplasia affects younger women and may present with accelerating hypertension. Abdominal bruit provides a clinical clue but is neither sensitive nor specific. Diagnosis relies on imaging including renal artery duplex ultrasound, magnetic resonance angiography, or computed tomographic angiography. Medical management suffices for most atherosclerotic disease, while angioplasty benefits fibromuscular dysplasia patients.

Other secondary causes each present with characteristic features guiding evaluation. Pheochromocytoma causes episodic hypertension with the triad of headache, diaphoresis, and palpitations; diagnosis relies on plasma or urinary metanephrines. Cushing syndrome manifests with central obesity, violaceous striae, moon facies, and hyperglycemia; dexamethasone suppression testing screens for hypercortisolism. Hypothyroidism classically elevates diastolic pressure and presents with fatigue and other systemic symptoms. Hyperthyroidism produces systolic hypertension with widened pulse pressure alongside tachycardia and weight loss. Coarctation of the aorta presents in younger patients with upper extremity hypertension, lower extremity hypotension, delayed femoral pulses, and arm-leg blood pressure discrepancy.

<image>Panel A: Clinical clues suggesting secondary hypertension organized by age, treatment response, and presentation features. Panel B: Primary aldosteronism evaluation pathway from screening through confirmation to treatment. Panel C: Renal artery stenosis comparison between atherosclerotic and fibromuscular dysplasia subtypes. Panel D: Secondary hypertension causes with classic presentations and initial diagnostic tests.</image>

IX. Hypertensive Emergencies

Hypertensive emergency and urgency represent distinct clinical entities requiring different management approaches. Hypertensive emergency combines severely elevated blood pressure, typically systolic above 180 mmHg or diastolic above 120 mmHg, with evidence of acute target organ damage requiring immediate blood pressure reduction. Hypertensive urgency describes similar blood pressure elevation without acute organ damage, allowing more gradual pressure reduction over hours to days. This distinction determines treatment setting, medication choice, and blood pressure reduction pace, making accurate categorization essential.

Acute target organ damage defines hypertensive emergency and may manifest in multiple organ systems. Neurological emergencies include hypertensive encephalopathy with headache, confusion, and visual disturbances; ischemic or hemorrhagic stroke; and posterior reversible encephalopathy syndrome. Cardiovascular emergencies encompass acute coronary syndrome, acute decompensated heart failure, and aortic dissection requiring immediate blood pressure control. Renal involvement produces acute kidney injury with oliguria and rising creatinine. Ophthalmologic emergency presents as papilledema with hemorrhages indicating malignant hypertension. Eclampsia represents hypertensive emergency in pregnancy with seizures and potential HELLP syndrome.

Hypertensive emergency management requires intensive care monitoring and careful intravenous therapy. Initial blood pressure reduction should lower mean arterial pressure by ten to twenty percent within the first hour, avoiding excessive reduction that may precipitate ischemic complications. Subsequent goals target 160/100 to 110 mmHg over the following two to six hours if initial reduction is tolerated. Preferred intravenous agents include labetalol providing combined alpha and beta blockade, nicardipine offering titratable calcium channel blockade, and clevidipine for rapid onset and offset. Sodium nitroprusside remains useful for severe cases but requires close monitoring due to cyanide toxicity risk with prolonged use. Specific target organ damage may require tailored therapy, such as nitroglycerin for acute coronary syndrome.

Hypertensive urgency with severely elevated blood pressure but no acute organ damage typically allows outpatient management with oral medications. Careful evaluation must exclude subtle target organ damage through history, examination, and basic testing before concluding urgency rather than emergency. Treatment involves resuming or adjusting oral antihypertensive medications rather than acute intravenous reduction. Blood pressure should decrease gradually over hours to days rather than immediately. Close follow-up within two to seven days confirms response and allows further adjustment. Patient education emphasizes medication adherence and recognition of warning symptoms that should prompt emergency evaluation.

<image>Panel A: Hypertensive emergency versus urgency comparison by blood pressure, organ damage, and management approach. Panel B: Target organ damage manifestations by organ system with clinical presentations. Panel C: Emergency blood pressure reduction targets and timeline with intravenous agent options. Panel D: Urgency management approach with oral medication adjustment and follow-up schedule.</image>

X. Cardiovascular Risk Reduction

Comprehensive cardiovascular risk reduction requires addressing multiple modifiable risk factors beyond blood pressure alone. Blood pressure control targeting below 130/80 mmHg reduces stroke and heart disease risk substantially. Lipid management through appropriate statin therapy addresses another major modifiable factor, with intensity matched to baseline risk. Diabetes management targeting hemoglobin A1c below seven percent for most patients prevents microvascular and macrovascular complications. Smoking cessation provides cardiovascular benefit exceeding that of any medication. Weight management and regular physical activity improve multiple risk factors simultaneously.

Statin therapy intensity should match cardiovascular risk level based on established guidelines. High-intensity statins producing greater than fifty percent LDL reduction are indicated for patients with clinical atherosclerotic cardiovascular disease, LDL at or above 190 mg/dL, diabetes in adults aged 40 to 75, or ten-year ASCVD risk at or above twenty percent. Moderate-intensity statins producing thirty to fifty percent LDL reduction are appropriate for patients with diabetes aged 40 to 75 without additional high-risk features and for intermediate-risk patients after shared decision-making discussion. Statin intolerance claims require careful evaluation, as true intolerance is uncommon and alternative statins or dosing strategies often prove tolerable.

Aspirin recommendations have evolved to more selective use for primary prevention. Secondary prevention in patients with established atherosclerotic cardiovascular disease clearly benefits from aspirin therapy. Primary prevention in patients without known cardiovascular disease requires careful consideration of bleeding risk, as routine aspirin use in low-risk populations may cause net harm. Individual decision-making incorporating cardiovascular and bleeding risk estimates guides aspirin recommendations for intermediate-risk primary prevention patients. Following coronary stenting or acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is indicated for defined periods.

Addressing all modifiable risk factors maximizes cardiovascular protection through synergistic benefits. Global risk assessment contextualizes individual factors within the complete risk profile. Diabetes management increasingly emphasizes SGLT2 inhibitors and GLP-1 receptor agonists for their cardiovascular protective effects beyond glucose lowering. Weight management improves blood pressure, lipids, and glucose while reducing overall cardiovascular risk. Depression treatment addresses a significant risk factor that also impairs adherence to other therapies. Sleep apnea screening and treatment addresses a common contributor to hypertension and cardiovascular disease. Integrating these elements creates a comprehensive cardiovascular risk reduction strategy.

<image>Panel A: Comprehensive cardiovascular risk factor checklist with target values for each. Panel B: Statin intensity recommendations by risk category with LDL reduction goals. Panel C: Aspirin decision framework distinguishing secondary from primary prevention considerations. Panel D: Integrated cardiovascular risk reduction strategy addressing all modifiable factors.</image>

Summary

• Blood pressure measurement requires proper technique including rest, positioning, cuff sizing, and averaging multiple readings
• Classification categories include normal (below 120/80), elevated (120-129/below 80), stage 1 (130-139/80-89), and stage 2 (at or above 140/90)
• Target blood pressure is below 130/80 mmHg for most patients including those with diabetes, chronic kidney disease, and elevated cardiovascular risk
• Lifestyle modifications include DASH diet producing approximately eleven mmHg reduction, sodium reduction (five to six mmHg), and exercise (five to eight mmHg)
• First-line medications include thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers; black patients respond best to diuretics or calcium channel blockers as initial therapy
• Medication selection should match comorbidities: ACE inhibitors or ARBs for diabetes with proteinuria or chronic kidney disease; beta-blockers following myocardial infarction
• Resistant hypertension is defined as blood pressure above goal on three or more medications including a diuretic; spironolactone addition is highly effective
• Secondary hypertension should be considered in patients under age 30, those with resistant hypertension, or those with sudden onset; screen for primary aldosteronism
• Hypertensive emergency combines severe elevation with acute target organ damage requiring careful reduction of mean arterial pressure by ten to twenty percent in the first hour
• Cardiovascular risk reduction requires comprehensive approach addressing blood pressure, lipids, diabetes, smoking, and weight

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown